Asymptomatic adults may be reservoirs of Streptococcus pneumoniae
(Instituto de Tecnologia Qu í mica e Biol ó gica Ant ó nio Xavier da Universidade NOVA de Lisboa ITQB NOVA) In Europe, S. pneumoniae is the most common cause of community-acquired bacterial pneumonia in adults. Still, very little is known about its colonization within this age group. A team of researchers from ITQB NOVA has now taken a crucial step to clarify the dynamics of carriage of this bacterium in adults. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 5, 2021 Category: Infectious Diseases Source Type: news

Paratek Pharmaceuticals Announces FDA Approval of Nuzyra (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Rates of Macrolide Resistance in S. pneumoniae High Across the U.S.
Clinicians should consider alternatives to macrolide monotherapy as empiric therapy for suspected community - acquired bacterial pneumonia (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 17, 2021 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Online COVID-19 Symptom Checkers May Not Catch Severe Illnesses Online COVID-19 Symptom Checkers May Not Catch Severe Illnesses
Digital COVID-19 symptom checkers in the US and the UK may fail to identify severe COVID-19 and other serious illnesses such as bacterial pneumonia or sepsis, according to a group of public health researchers.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

New study explains important cause of fatal influenza
(Karolinska Institutet) It is largely unknown why influenza infections lead to an increased risk of bacterial pneumonia. Researchers at Karolinska Institutet in Sweden have now described important findings leading to so-called superinfections, which claim many lives around the world every year. The study is published in the journalPNAS,Proceedings of the National Academy of Sciences, and can also contribute to research on COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 25, 2020 Category: Infectious Diseases Source Type: news

Genetic analysis system yields new insights into bacterial pneumonia
(University of California - Santa Cruz) A team of infectious disease researchers has developed a new method to identify virulence genes in Streptococcus pneumoniae, the leading cause of bacterial pneumonia. Using this technique in a mouse model of pneumonia, they were able to gain new insights into the progression of the disease and its interaction with the flu virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 28, 2020 Category: Infectious Diseases Source Type: news

Uganda: Acholi Health Centres Hit By Drug Shortage
[Monitor] Living four kilometres off the neighbourhood of Ongako Health Centre III in Ongako Sub-county, Omoro District, Ms Ritah Arac, arrives with her 7-year-old son, who has been ill for a week.An hour later, her son is diagnosed with bacterial pneumonia. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - October 7, 2020 Category: African Health Source Type: news

FDA Approves Fetroja (cefiderocol) for the Treatment of Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
OSAKA, Japan& FLORHAM PARK, N.J.--(BUSINESS WIRE) September 28, 2020 --Shionogi& Co., Ltd. (hereafter“Shionogi”) today announces that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2020 Category: Drugs & Pharmacology Source Type: news

Ontario health-care worker returns home six months after testing positive for COVID-19
Six months ago, cross-border health-care worker Torry Robertson of LaSalle, Ont., contracted COVID-19 — leading to renal failure, a super bug, bacterial pneumonia and almost 40 days connected to a ventilator. But Friday, he was finally given the green light to go home, with neighbours, friends and family members cheering him on. (Source: CBC | Health)
Source: CBC | Health - September 19, 2020 Category: Consumer Health News Tags: News/Canada/Windsor Source Type: news

Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia Recarbrio Effective for Hospital-Acquired Bacterial Pneumonia
Recarbrio is noninferior to piperacillin/tazobactam for treating adults with hospital-acquired or ventilator-associated bacterial pneumonia, according to results from the RESTORE-IMI 2 trial.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 26, 2020 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment
Clinical / Antimicrobial (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Merck ’s Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
KENILWORTH, N.J.--(BUSINESS WIRE) June 5, 2020 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 5, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
The FDA has approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Leave Clothes Out In The Sun? Do Flu Shots Protect? Dr. Mallika Marshall Answers Your Coronavirus Questions
BOSTON (CBS) — As Massachusetts continues to fight the coronavirus pandemic, the public has plenty of questions. Dr. Mallika Marshall answered some of those sent to her email (drmallika@cbs.com) and Facebook and Twitter accounts. I want know why all of these surgeries have been canceled. Mine was canceled and I’m in a lot of pain. – Trish, Canada Not just in Canada. Elective and nonemergency surgeries have been postponed throughout the U.S. in an effort to protect patients, healthcare workers, and free up hospital beds. Hospitals are anxious to resume elective surgeries, but the a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 15, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news

COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital [NG173], NICE (published 1st May 2020)
The guideline emphasises the importance of careful antibiotic prescribing and prompt review after testing. It is important to note that during the COVID ‑19 pandemic, most cases of pneumonia have been viral and therefore antibiotics are ineffective unless there is a bacterial co-infection. For patients with suspected or confirmed bacterial pneumonia, a broad-spectrum antibiotic should be given as soon as possible unless there is significant confid ence about the absence of bacterial co-infection. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 1, 2020 Category: Consumer Health News Source Type: news

How Safe Is The Meat Supply Chain? Dr. Mallika Marshall Answers Your Coronavirus Questions
BOSTON (CBS) – As the number of coronavirus cases continues to grow, we are receiving a number of questions from the public. Dr. Mallika Marshall answered some of the questions sent to WBZ-TV’s Facebook, Instagram and Twitter accounts. What does ‘non-conclusive’ mean regarding COVID-19 test results? – Karen, Facebook An inconclusive test means it can’t confirm whether a patient is positive or negative for the coronavirus. The current test looks for the presence of two genes associated with the virus. If both genes are found, the test is positive. If neither is found, it’s nega...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 29, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Healthwatch Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news

As virus advances, doctors rethink rush to ventilators
The picture is partial and evolving, but it suggests people with COVID-19 who have been intubated have had, at least in the early stages of the pandemic, a higher rate of death than other patients on ventilators who have conditions such as bacterial pneumonia or collapsed lungs. (Source: The Economic Times)
Source: The Economic Times - April 26, 2020 Category: Consumer Health News Source Type: news

COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community [NG165], NICE (updated 23rd April 2020)
Latest update: 23 April 2020 The recommendations on antibiotic treatment for bacterial pneumonia in the community during the COVID-19 pandemic were clarified. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 24, 2020 Category: Consumer Health News Source Type: news

Why Some Doctors Are Now Moving Away From Ventilator Treatments for Coronavirus Patients
(NEW YORK) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can. The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients. Read more: Front Line Workers Tell Their Own Stories in the New Issue of TIME The evolving treatments highlight the fact that doctors are still learning the best way to manage a virus that emerged only months ago. They are relying on anecdotal, real-t...
Source: TIME: Health - April 9, 2020 Category: Consumer Health News Authors: Mike Stobbe / AP Tags: Uncategorized COVID-19 News Desk wire Source Type: news

President Trump Called Hydroxychloroquine a ‘Game Changer,’ But Experts Warn Against Self-Medicating With the Drug. Here’s What You Need to Know
After President Trump, late last week, expressed great confidence in the promise of a new COVID-19 therapy that combines two existing prescription medications, supplies of these two drugs rapidly began disappearing from pharmacy shelves. The U.S. Food and Drug Administration allowed an Indian company previously restricted from importing drug products into the US to now start manufacturing one of the drugs. And U.S. plants began gearing up to produce enough to meet the surge in demand. But in those few days, a few people who began self medicating with the drugs in an effort to prevent COVID-19 have died, and others have bee...
Source: TIME: Health - March 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Removing body clock gene protects mice against pneumonia
(University of Oxford) This is the first time a clock gene has been found to affect resistance to bacterial pneumonia, a fatal disease responsible for 5% of all deaths in the UK each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2020 Category: International Medicine & Public Health Source Type: news

Skin and mucous membrane lesions as complication of pneumonia
(University of Zurich) Painful inflammatory lesions of the skin and mucous membranes may occur in children who develop bacterial pneumonia. A research group at the University Children's Hospital Zurich has recently developed a new diagnostic blood test, which reliably diagnoses bacteria as the causative pathogen at an early stage, allowing more specific treatment and prediction about prognosis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 19, 2019 Category: Infectious Diseases Source Type: news

Up to 43% of Antibiotic Prescriptions in the U.S. Are Unnecessary or Improperly Written, Analysis Finds
The World Health Organization earlier this year called antimicrobial resistance—pathogens’ ability to evade medical interventions—one of the 10 largest threats to global health. In the U.S. alone, according to a recent Centers for Disease Control and Prevention (CDC) report, 35,000 people die each year due to antibiotic-resistant infections. A new study published in the BMJ points to one major propagator of the problem: doctors are prescribing antibiotics when they shouldn’t. In fact, up to 43% of U.S. antibiotic prescriptions may be “inappropriate,” according to the research. Antibioti...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Research Source Type: news

FDA Approves New Indication for Delafloxacin for CABP FDA Approves New Indication for Delafloxacin for CABP
Following approval in 2017 for bacteria skin infections, the fluoroquinolone antibiotic is now indicated for adults with community-acquired bacterial pneumonia.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 25, 2019 Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news

FDA Approves Baxdela (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
MORRISTOWN, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 24, 2019 Category: Drugs & Pharmacology Source Type: news

New Antibiotic Approved for Community-Acquired Bacterial Pneumonia
Title: New Antibiotic Approved for Community-Acquired Bacterial PneumoniaCategory: Health NewsCreated: 8/19/2019 12:00:00 AMLast Editorial Review: 8/20/2019 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - August 20, 2019 Category: Respiratory Medicine Source Type: news

FDA approves King of Prussia company's pneumonia drug
The Food and Drug Administration approved Nabriva Therapeutics' drug application for its antibiotic Xenleta. Xenleta treats community-acquired bacterial pneumonia (CABP), a leading cause of infection-related deaths in the United States. Nabriva's stock was up 20% at $2.67 per share in after-hours trading Monday. According to the company, about 5 million cases of pneumonia are reported in the United Sta tes each year, and pneumonia is the fifth-leading cause of hospitalizations. Nabriva said Xenleta… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: John George Source Type: news

FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP FDA OKs First-in-Class Antibiotic Lefamulin (Xenleta) for CABP
The new semisynthetic pleuromutilin antibiotic will be available for oral and IV administration with a short 5- to 7-day course of therapy for community-acquired bacterial pneumonia (CABP).FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 19, 2019 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

FDA Approves Xenleta (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP)
DUBLIN, Ireland, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 19, 2019 Category: Drugs & Pharmacology Source Type: news

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
The FDA approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 19, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New Antibiotic Xenleta Approved for Community-Acquired Bacterial Pneumonia
MONDAY, Aug. 19, 2019 -- Xenleta (lefamulin) has been approved to treat adults with community-acquired bacterial pneumonia, the U.S. Food and Drug Administration announced today. Dosing of Xenleta is either an oral administration of 600 mg every 12... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 19, 2019 Category: General Medicine Source Type: news

Practical Tips for Diagnosing and Treating Bacterial Pneumonia in the Nursing Home
A clinical diagnosis of bacterial pneumonia in nursing home residents most often can be treated with a single oral course of antibiotic therapy targeted toward community-acquired pneumonia pathogens, Ghinwa Dumyati, MD, said at the AMDA — The Society for Post-Acute and Long-Term Care Medicine’s annual conference. (Source: Caring for the Ages)
Source: Caring for the Ages - July 30, 2019 Category: Health Management Authors: Christine Kilgore Source Type: news

Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 11, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 11, 2019 Category: General Medicine Source Type: news

FDA expands Merck antibiotic indication to pneumonia treatment
The previously FDA-approved drug, Zerbaxa, is now indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 4, 2019 Category: Pharmaceuticals Source Type: news

Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia
TUESDAY, June 4, 2019 -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2019 Category: Pharmaceuticals Source Type: news

FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia
FDA today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 4, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia Dual Antibiotic Zerbaxa Gets FDA Nod for Bacterial Pneumonia
Zerbaxa (ceftolozane and tazobactam) for hospital- and ventilator-associated bacterial pneumonia was initially approved for complicated intra-abdominal and urinary tract infections.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 4, 2019 Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news

FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Monday, June 3, 2019 -- KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Merck’s supplemental New Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 3, 2019 Category: Drugs & Pharmacology Source Type: news

Merck wins U.S. FDA approval for expanded use of antibiotic
The U.S. Food and Drug Administration said https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia on Monday it approved expanded use of Merck& Co Inc's antibiotic to treat hospital-acquired pneumonia in patients 18 years and older. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Characteristics and Outcomes of Patients With and Without Type 2 Diabetes Mellitus and Pulmonary Sepsis
To date, studies have provided conflicting results regarding the impact of type 2 diabetes mellitus (DM) on sepsis-related outcomes. Our objective is to understand the impact of type 2 DM in bacterial pneumonia and sepsis-related intensive care unit (ICU) outcomes. Our findings demonstrated that type 2 DM does not increase the overall mortality. Our findings of increased mortality in both type 2 DM patients with lower admission glucose, and non-DM patients with higher mean glucose during the hospital stay needs to be further evaluated. Future studies in regards to this could lead to personalized glucose treatment goals for...
Source: Current Awareness Service for Health (CASH) - April 25, 2019 Category: Consumer Health News Source Type: news

Omadacycline Found Similar to Usual Care for CABP, ABSSSI (CME/CE)
(MedPage Today) -- Well-tolerated option for select patients with community-acquired bacterial pneumonia and skin infections (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 13, 2019 Category: Infectious Diseases Source Type: news

Omadacycline Noninferior to Moxifloxacin for Pneumonia
WEDNESDAY, Feb. 6, 2019 -- Omadacycline is noninferior to moxifloxacin for community-acquired bacterial pneumonia and noninferior to linezolid for acute bacterial skin infections, according to two studies published in the Feb. 7 issue of the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Second Child In Mass. Dies From Flu-Related Illness
BOSTON (CBS) — A four-year-old girl from Framingham has died from a flu-related illness, the second flu-related death of a child in Massachusetts this week, the Framingham Public Health Department announced Friday. According to the DPH, the cases are unrelated “and were confirmed by the DPH’s State Public Health Laboratory.” The death of a 12-year-old boy from Milford with a flu-related illness was announced Thursday. The boy’s mother told WBZ-TV he got his flu shot this year, but still got sick. He stayed home from school for multiple days until he developed a bacterial in...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 1, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Seen On WBZ-TV Syndicated Local Flu Flu Deaths Local TV Source Type: news

What Are Common Causes of Blindness in Children?
Discussion According to the World Health Organization, about 1.3 billion people have some form of visual impairment. Most people with visual impairments are>50 years old, more are female than male, and more live in resource-limited areas than resource-rich areas. Most visual impairments are avoidable (80%) in all age groups with the leading causes globally and across ages being uncorrected refractive errors and cataracts. The most common causes of blindness are: Refractive errors, uncorrected Cataract Age-related macular degeneration Glaucoma Diabetic retinopathy Corneal opacity Trachoma The exact numbers vary by regi...
Source: PediatricEducation.org - January 28, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

A traditional Chinese medicine proves effective in treating bacterial pneumonia
(Natural News) A herbal compound used in traditional Chinese medicine can be used to treat a type of pneumonia caused by multidrug-resistant bacteria, according to researchers from the Henan University of Chinese Medicine. In their study, which was published in BMC Complementary and Alternative Medicine, they suggested that Dusuqing granules have the ability to inhibit the effects of Klebsiella... (Source: NaturalNews.com)
Source: NaturalNews.com - January 21, 2019 Category: Consumer Health News Source Type: news

Antibiotic developer Nabriva enters into $75M loan deal
With two potential product launches on the horizon, Nabriva Therapeutics has entered into loan agreement valued at up to $75 million with Hercules Capital. Earlier this week, Nabriva (NASDAQ: NBRV) filed two new drug applications seeking approval for intravenous and oral formulations of Lefamulin to treat community-acquired bacterial pneumonia. Last month the company — which is based in Dublin, Ireland, and has its U.S. headquarters in King of Pru ssia — filed a new drug application for Contepo,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 21, 2018 Category: American Health Authors: John George Source Type: news

Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment
Nabriva Therapeutics on Thursday submitted two new drug applications with the Food and Drug Administration seeking marketing approval for intravenous and oral formulation of Lefamulin to treat community-acquired bacterial pneumonia in adults. “The submission of the Lefamulin NDAs marks another major milestone for Nabriva, demonstrating our commitment to develop novel anti-infective agents that address the urgent, unmet medical need faced by patients with serious infections,” said Dr. Jennifer… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 20, 2018 Category: Health Management Authors: John George Source Type: news

Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 20, 2018 Category: Drugs & Pharmacology Source Type: news

With these nanoparticles, a simple urine test could diagnose bacterial pneumonia
(Massachusetts Institute of Technology) MIT researchers have now developed a nanoparticle-based technology that could be used distinguish between bacterial and viral forms of pneumonia. The technology could also be used to monitor whether antibiotic therapy has successfully treated the infection. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 29, 2018 Category: Infectious Diseases Source Type: news